Federal Pharmaceuticals (03933): UBT48128 tablets were approved for clinical trials by the US FDA

Zhitong Finance App News, Federal Pharmaceuticals (03933) announced that the New Drug Clinical Trial Registration Application (IND) for UBT48128 tablets, a Class 1 innovative drug independently developed by Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, was approved by the US Food and Drug Administration (FDA). The IND numbers are 182060 and 182061, respectively.

UBT48128 is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist that reduces blood sugar and weight by promoting insulin secretion while controlling appetite and regulating energy metabolism. Preclinical studies in various animal models have shown that UBT48128 can significantly reduce body weight and blood sugar, and the weight loss effect is superior to similar products currently on the market. This product is expected to show good treatment benefits for overweight or obesity and type 2 diabetes.

In the future, the company will continue to work on new product research and development, and focus on enhancing competitiveness and creativity in the biomedical industry, deepening the field of chronic disease treatment, and providing clinical services and benefiting patients with better products and better pipelines, which is expected to generate greater benefits for the company and its shareholders.